Two Sigma Investments LP bought a new position in Sienna Biopharmaceuticals Inc (NASDAQ:SNNA) during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm bought 64,074 shares of the company’s stock, valued at approximately $149,000. Two Sigma Investments LP owned approximately 0.30% of Sienna Biopharmaceuticals at the end of the most recent reporting period.
Several other institutional investors have also recently added to or reduced their stakes in SNNA. Dimensional Fund Advisors LP purchased a new position in shares of Sienna Biopharmaceuticals in the fourth quarter worth approximately $36,000. Rhumbline Advisers increased its position in shares of Sienna Biopharmaceuticals by 52.9% in the fourth quarter. Rhumbline Advisers now owns 19,377 shares of the company’s stock worth $45,000 after acquiring an additional 6,702 shares in the last quarter. Raymond James & Associates purchased a new position in shares of Sienna Biopharmaceuticals in the fourth quarter worth approximately $54,000. SG Americas Securities LLC purchased a new position in shares of Sienna Biopharmaceuticals in the fourth quarter worth approximately $78,000. Finally, Jane Street Group LLC purchased a new position in shares of Sienna Biopharmaceuticals in the third quarter worth approximately $182,000. 30.59% of the stock is currently owned by institutional investors and hedge funds.
SNNA stock opened at $2.07 on Wednesday. The company has a quick ratio of 2.07, a current ratio of 2.07 and a debt-to-equity ratio of 1.13. The company has a market cap of $61.97 million, a P/E ratio of -0.58 and a beta of 3.64. Sienna Biopharmaceuticals Inc has a 52 week low of $1.93 and a 52 week high of $21.53.
Several research firms have recently weighed in on SNNA. Zacks Investment Research raised shares of Sienna Biopharmaceuticals from a “hold” rating to a “buy” rating and set a $3.50 target price on the stock in a research report on Wednesday, December 19th. ValuEngine cut shares of Sienna Biopharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday, January 24th.
TRADEMARK VIOLATION NOTICE: This article was first published by Ticker Report and is owned by of Ticker Report. If you are accessing this article on another domain, it was illegally stolen and reposted in violation of international copyright law. The original version of this article can be read at https://www.tickerreport.com/banking-finance/4299589/two-sigma-investments-lp-takes-position-in-sienna-biopharmaceuticals-inc-snna.html.
Sienna Biopharmaceuticals Profile
Sienna Biopharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of topical products in medical dermatology and aesthetics. The company's lead product candidates include SNA-120, a first-in-class inhibitor of tropomyosin receptor kinase A, which is in a Phase IIb clinical trial for the treatment of pruritus or itch associated with psoriasis, as well as for psoriasis; and SNA-125, a topical janus kinase 3 inhibitor that is in Phase I/II clinical trials for the treatment of atopic dermatitis, psoriasis, and pruritus.
Featured Article: Balance Sheet
Receive News & Ratings for Sienna Biopharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sienna Biopharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.